FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Sebastian Stintzing, Ursula Vehling‐Kaiser et al.|The Lancet Oncology|2014Cited by 1.7k
Systemic Infection with<i>Mycobacterium genavense</i>Following Immunosuppressive Therapy in a Patient Who Was Seronegative for Human Immunodeficiency VirusChristian Bogdan, Werner Solbach, P. M. Kern et al.|Clinical Infectious Diseases|1997Cited by 35